Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01526343 · ClinicalTrials.gov registry record · Phase 2
Medtronic Reveal XT Study
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT01526343 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 47 participants.
The verdict
NCT01526343, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
While surgical treatment for atrial fibrillation (AF) has been performed for over 20 years, virtually all of the historical series reported only the recurrence of symptomatic AF and have used only intermittent electrocardiogram (ECG) follow-up. This study compares the use of traditional arrhythmia assessment (ECG and 24-hour holter monitoring) with the use of the Medtronic Reveal XT device to continuously record heart rhythm to quantify postoperative arrhythmia burden following surgical treatment for AF in patients undergoing either lone or concomitant heart surgery.
Interventions
- DEVICE Reveal XT implantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2011-06 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01526343
The ClinicalTrials.gov registry entry for NCT01526343 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Reveal XT implantation is the first listed.
NCT01526343 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01526343 about?
NCT01526343 is a clinical study titled "Medtronic Reveal XT Study". While surgical treatment for atrial fibrillation (AF) has been performed for over 20 years, virtually all of the historical series reported only the recurrence of symptomatic AF and have used only intermittent electrocardiogram (ECG) follow-up. This study compares the use of traditional arrhythmia a...
What is the current status of trial NCT01526343?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2011-06. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01526343?
The interventions under investigation include: Reveal XT implantation (DEVICE).
Who is sponsoring clinical trial NCT01526343?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.